Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana C Anderson

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
JCI Insight|March 13, 2020
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicityUgur Eskiocak, Wilson Guzman, Benjamin Wolf, et al.
Nature|March 17, 2016
Corrigendum: CEACAM1 regulates TIM-3-mediated tolerance and exhaustionYu-Hwa Huang, Chen Zhu, Yasuyuki Kondo, et al.
Nature|November 4, 2014
CEACAM1 regulates TIM-3-mediated tolerance and exhaustionYu-Hwa Huang, Chen Zhu, Yasuyuki Kondo, et al.
Mucosal Immunology|June 26, 2024
Dietary protein modulates intestinal dendritic cells to establish mucosal homeostasisThais G Moreira, Laura M Cox, Patrick Da Silva, et al.
Nature|February 9, 2024
Author Correction: CEACAM1 regulates TIM-3-mediated tolerance and exhaustionYu-Hwa Huang, Chen Zhu, Yasuyuki Kondo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2020
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in GlioblastomaJ Bryan Iorgulescu, Prafulla C Gokhale, Maria C Speranza, et al.
Immunity|June 12, 2026
Interleukin 23 promotes a pro-inflammatory Th17 cell state by stabilizing RORγt and suppressing glucocorticoid receptor activityDandan Yang, Linglin Huang, Jianfei Yang, et al.
Cancer Discovery|November 9, 2019
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor ImmunityXian-Yang Li, Achim K Moesta, Christos Xiao, et al.
The Journal of Clinical Investigation|March 22, 2022
Tim-3 mediates T cell trogocytosis to limit antitumor immunityOrnella Pagliano, Robert M Morrison, Joe-Marc Chauvin, et al.
Cancer Cell|October 6, 2023
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memoryIker Ausejo-Mauleon, Sara Labiano, Daniel de la Nava, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
JCI Insight|March 13, 2020
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicityUgur Eskiocak, Wilson Guzman, Benjamin Wolf, et al.
Nature|March 17, 2016
Corrigendum: CEACAM1 regulates TIM-3-mediated tolerance and exhaustionYu-Hwa Huang, Chen Zhu, Yasuyuki Kondo, et al.
Nature|November 4, 2014
CEACAM1 regulates TIM-3-mediated tolerance and exhaustionYu-Hwa Huang, Chen Zhu, Yasuyuki Kondo, et al.
Mucosal Immunology|June 26, 2024
Dietary protein modulates intestinal dendritic cells to establish mucosal homeostasisThais G Moreira, Laura M Cox, Patrick Da Silva, et al.
Nature|February 9, 2024
Author Correction: CEACAM1 regulates TIM-3-mediated tolerance and exhaustionYu-Hwa Huang, Chen Zhu, Yasuyuki Kondo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2020
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in GlioblastomaJ Bryan Iorgulescu, Prafulla C Gokhale, Maria C Speranza, et al.
Immunity|June 12, 2026
Interleukin 23 promotes a pro-inflammatory Th17 cell state by stabilizing RORγt and suppressing glucocorticoid receptor activityDandan Yang, Linglin Huang, Jianfei Yang, et al.
Cancer Discovery|November 9, 2019
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor ImmunityXian-Yang Li, Achim K Moesta, Christos Xiao, et al.
The Journal of Clinical Investigation|March 22, 2022
Tim-3 mediates T cell trogocytosis to limit antitumor immunityOrnella Pagliano, Robert M Morrison, Joe-Marc Chauvin, et al.
Cancer Cell|October 6, 2023
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memoryIker Ausejo-Mauleon, Sara Labiano, Daniel de la Nava, et al.
Pageof 11